Background And Aims: External counter-pulsation (ECP) generates sheer stress thereby improving endothelial function and anginal symptoms in coronary artery disease. Endothelial dysfunction is also involved in the pathogenesis of T2DM. The aim of this pilot study was to investigate the use of ECP at different doses in improving endothelial function and glycaemic markers in T2DM.
Methods: This prospective study involved 46 subjects with T2DM randomly assigned to receive 35 sessions of ECP at different regimens (0.5 h versus 1 h) and duration (7 versus 12 weeks). Endothelial function was evaluated by reactive hyperaemia index (RHI) via peripheral arterial tonometry at the start, midpoint and end of study. Other secondary outcomes included fasting glucose, HOMA-IR, HbA1c, blood pressure, lipid profile, weight and vibration sense.
Results: There was no change in RHI across all 3 regimens of ECP individually or collectively at the end of the study (ΔRHI +0.01%, p = 0.458). Glycaemic markers also remained unchanged at endpoint. Subgroup analysis showed an improvement in RHI (ΔRHI +20.6%, p = 0.0178) in subjects with more severe endothelial dysfunction at baseline.
Conclusion: ECP did not show a beneficial effect on endothelial function or glycemic control in this South-East Asian population with T2DM at any of the three regimens. This may partly be explained by less severe endothelial dysfunction and less insulin resistance in our population at baseline.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.dsx.2020.11.003 | DOI Listing |
Malays J Pathol
December 2024
Universiti Kebangsaan Malaysia, Faculty of Medicine, Department of Pathology, 56000 Kuala Lumpur, Malaysia.
Introduction: ICAM-1 is an adhesion molecule expressed on the endothelial cells and is involved in regulating leukocyte recruitment to the site of inflammation. Elevated ICAM-1 mRNA expression was found in the serum of mothers with chorioamnionitis. This study aimed to determine the expression of ICAM-1 in the placenta and umbilical cord of pregnancy with chorioamnionitis, and its association with adverse neonatal outcome.
View Article and Find Full Text PDFBrain Pathol
December 2024
Laboratory of Neurobiology and Molecular Therapeutics, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.
Amyotrophic lateral sclerosis (ALS) is a fatal neuromuscular disease with no effective treatments, in part caused by variations in progression and the absence of biomarkers. Mice carrying the SOD1G93A transgene with different genetic backgrounds show variable disease rates, reflecting the diversity of patients. While extensive research has been done on the involvement of the central nervous system, the role of skeletal muscle remains underexplored.
View Article and Find Full Text PDFZh Nevrol Psikhiatr Im S S Korsakova
December 2024
Kazan (Volga region) Federal University, Kazan, Russia.
Cerebrovascular diseases themselves are the second most common cause of cognitive impairment (dementia). In addition, cerebral small vessel disease (CSVD) makes a significant contribution to the clinical picture of neurodegenerative diseases. Since there are currently no pharmacological treatments for CSVD, a promising method is the activation of the endogenous mechanisms of sanogenesis.
View Article and Find Full Text PDFUnlabelled: Diabetic macular edema (DME) is a leading cause of visual impairment and blindness among diabetic patients, its prevalence is continuing to increase worldwide. Faricimab, a bispecific antibody, represents a new generation of treatments for DME.
Purpose: This study presents an indirect comparison of the effectiveness and safety of faricimab versus other treatment options for DME.
Purpose: This study evaluates the efficacy of intravitreal injections (IVI) of faricimab in patients with neovascular age-related macular degeneration (nAMD) and retinal pigment epithelium detachment (RPED) resistant to other anti-VEGF agents.
Material And Methods: The study included 61 patients (61 eyes) with nAMD previously treated with aflibercept and/or brolucizumab IVIs. Three groups were formed: group 1 received aflibercept IVI (32 eyes), group 2 received brolucizumab IVI (14 eyes), and group 3 received aflibercept followed by brolucizumab IVI (15 eyes).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!